Rallybio Corporation (RLYB), a clinical-stage biotechnology company, has implemented a 1-for-8 reverse stock split effective February 6, 2026, as a critical move to regain listing compliance on the Nasdaq exchange. The action represents a significant milestone—and market reality check—for the compan